Literature DB >> 21905446

High prevalence of iatrogenic hyperthyroidism in elderly patients with atrial fibrillation in an anticoagulation clinic.

Sandeep Kumar Krishnan1, Mary L Dohrmann, Stephen A Brietzke, David A Fleming, Greg C Flaker.   

Abstract

In elderly patients with established atrial fibrillation (AF) who are receiving thyroid replacement, regular testing for thyroid function is often not performed, placing the patient at risk for iatrogenic hyperthyroidism. Of 215 patients followed in an anticoagulation clinic, 41 were receiving thyroid replacement and 15 of these were found to have hyperthyroidism. Eight had documented AF coincident with abnormal thyroid function. In addition, only 22 patients on thyroid replacement had an annual TSH. In conclusion, iatrogenic hyperthyroidism may frequently be missed in AF patients because of inadequate monitoring of serum TSH. Thyroid replacement is common in elderly patients with AF followed in an anticoagulation clinic. Laboratory evidence of hyperthyroidism occurred in 37%, usually in patients with higher doses of thyroid replacement, and often associated with AF. The frequency of iatrogenic hyperthyroidism may be underestimated in patients with AF since many patients who receive thyroid replacement therapy are not monitored regularly with serum TSH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21905446      PMCID: PMC6188434     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  14 in total

Review 1.  Clinical practice. Subclinical hyperthyroidism.

Authors:  A D Toft
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

2.  High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study.

Authors:  Jan Heeringa; E H Hoogendoorn; W M van der Deure; Albert Hofman; R P Peeters; W C J Hop; M den Heijer; Theo J Visser; Jacqueline C M Witteman
Journal:  Arch Intern Med       Date:  2008-11-10

3.  Subclinical hyperthyroidism as a risk factor for atrial fibrillation.

Authors:  J Auer; P Scheibner; T Mische; W Langsteger; O Eber; B Eber
Journal:  Am Heart J       Date:  2001-11       Impact factor: 4.749

4.  Thyroid status, cardiovascular risk, and mortality in older adults.

Authors:  Anne R Cappola; Linda P Fried; Alice M Arnold; Mark D Danese; Lewis H Kuller; Gregory L Burke; Russell P Tracy; Paul W Ladenson
Journal:  JAMA       Date:  2006-03-01       Impact factor: 56.272

Review 5.  Drug-induced atrial fibrillation.

Authors:  Cornelis S van der Hooft; Jan Heeringa; Gerard van Herpen; Jan A Kors; J Herre Kingma; Bruno H Ch Stricker
Journal:  J Am Coll Cardiol       Date:  2004-12-07       Impact factor: 24.094

6.  The Colorado thyroid disease prevalence study.

Authors:  G J Canaris; N R Manowitz; G Mayor; E C Ridgway
Journal:  Arch Intern Med       Date:  2000-02-28

7.  Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).

Authors:  Joseph G Hollowell; Norman W Staehling; W Dana Flanders; W Harry Hannon; Elaine W Gunter; Carole A Spencer; Lewis E Braverman
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

8.  The aging thyroid. The use of thyroid hormone in older persons.

Authors:  C T Sawin; A Geller; J M Hershman; W Castelli; P Bacharach
Journal:  JAMA       Date:  1989-05-12       Impact factor: 56.272

9.  Atrial fibrillation associated with exogenous subclinical hyperthyroidism, changing axis deviation, troponin-I positive and without acute coronary syndrome.

Authors:  Salvatore Patanè; Filippo Marte
Journal:  Int J Cardiol       Date:  2009-04-01       Impact factor: 4.164

10.  Levothyroxine replacement dose for primary hypothyroidism decreases with age.

Authors:  R L Rosenbaum; U S Barzel
Journal:  Ann Intern Med       Date:  1982-01       Impact factor: 25.391

View more
  1 in total

1.  Plasma endothelin-1 levels are increased in atrial fibrillation patients with hyperthyroidism.

Authors:  Fadia Mayyas; Nesreen Saadeh; Kusai Al-Muqbel; David R Van Wagoner
Journal:  PLoS One       Date:  2018-12-04       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.